A White House meeting with top pharmaceutical executives has been called off after Trump administration executive orders signed last Friday on the matter drew criticism from the pharmaceutical industry; Kodak won a US government loan of $ 765 million to help accelerate domestic production of drugs to treat several medical conditions and reduce US reliance on foreign supplies; more than a third of patients with mild illness from coronavirus disease 2019 (COVID-19) reported related symptoms that lasted 2-3 weeks after testing positive.
Drugmakers refuse to meet after Trump issues cost orders
Today, senior pharmaceutical executives were scheduled to meet with President Donald Trump at the White House to discuss drug prices, but the meeting was called off after the Trump administration’s decision decrees signed last Friday on the subject drew criticism from the pharmaceutical industry. As reported by POLITICS, one of the executive orders would require health officials to publish a plan linking Medicare payments for certain drugs to lower costs paid overseas. Some patient groups claim that the rule, known as the most-favored-nation rule, would stifle innovation and reduce access to drugs, and the pharmaceutical industry initially thought the rule would be dropped before the Friday announcement. Trump also said during the briefing that drugmakers have one month to come up with a better alternative to the rule.
Kodak Acquires US $ 765 Million Loan to Start Repairing Medical Supply Chain
The Wall Street Journal reports that Eastman Kodak Company, the former photography sales leader, has won a US government loan of $ 765 million to help accelerate domestic production of drugs to treat several medical conditions and reduce reliance on the United States towards foreign countries such as China and India. The loan is the first of its kind under the Defense Production Act, which the Trump administration had previously invoked to speed up production of supplies needed for the 2019 coronavirus disease (COVID-19). Kodak will now produce ingredients for generic drugs that include hydroxychloroquine, an antimalarial drug that the FDA warned against due to associated heart rhythm problems.
Study finds symptoms of COVID-19 persist in 35% of ambulatory patients
According to survey results published in the CDC Morbidity and Mortality Weekly Report, more than a third of patients (35%) with mild COVID-19 illness reported related symptoms that lasted 2-3 weeks after testing positive, with 1 in 5 reported previously as adults in good health. Reported by CIDRAP, the survey included 274 interviews that were conducted 14 to 21 days after the first positive test for COVID-19. According to the results, cough and fatigue were the symptoms least likely to go away after the interview period.